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“being too busy (2.5% Medicare; 17.2% commercial and “other reasons” (21.9% 
Medicare; 8.1% commercial) which included travel, being hospitalized or sick, disrup-
tion of daily events and unable to get to the pharmacy. Prescription copay was a 
barrier for <5% of respondents. Taking medications as part of a daily routine (46.4% 
Medicare; 52.2% commercial) helped improve adherence. Low non adherence 
(0–59%) was associated with higher cardiovascular related expenditures ($11,800) 
compared to moderate (60–79%) non adherence ($8467). CONCLUSIONS: Despite 
elaborate models explaining non adherence, forgetfulness was the primary reason for 
self reported non-adherence in this study. Events interfering with daily routine also 
had signiﬁcant impact on non-adherence. Novel interventions should address medica-
tion taking competency and promote a medication routine.
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OBJECTIVES: Dual-antiplatelet therapy with aspirin and thienopyridines is consid-
ered as the cornerstone in the treatment of acute coronary syndromes (ACS) undergo-
ing percutaneous coronary intervention (PCI). Recent ACC/AHA/SCAI guidelines on 
PCI recommend the use of clopidogrel or prasugrel for the treatment of ACS patients 
undergoing PCI with drug eluting or bare metal stents for at least a year. However, 
little is known about the factors that predict the use and adherence of clopidogrel in 
ACS-PCI patients. This study examined the predictors of clopidogrel use and adher-
ence in the employer-based MarketScan claims database. METHODS: Patients (N = 
10,456), aged 18–65 years, hospitalized with a primary diagnosis of ACS and under-
went PCI between January 1, 2005 and December 31, 2006, and had a prior 1-year 
insurance eligibility and drug information were identiﬁed. Adherence was deﬁned as 
medication possession ratio (MPR) of ≥80%. Multivariate logistic regression analyses 
were conducted to identify the predictors of clopidogrel use and adherence. RESULTS: 
Overall, 92.8% of ACS-PCI patients received a prescription of clopidogrel and 66.8% 
of the clopidogrel users were adherent. Receiving PCI without stenting (OR = 3.3), 
comorbid hypertension (OR = 1.50), diabetes (OR = 1.49), atrial ﬁbrillation (OR = 
1.87), and older age (OR = 1.01) were associated with decreased use of clopidogrel 
while prior use of clopidogrel (OR = 0.54) or other BASI (Beta-blocker, Antiplatelet 
agents, Statin, and ACE Inhibitor) (OR = 0.43) were associated with increased use of 
clopidogrel (all p-values <0.05). Factors signiﬁcantly associated with non-adherence 
of clopidogrel were: prior use of clopidogrel (OR = 1.41), prior hospitalization (OR 
= 1.34), chronic pulmonary disease (OR = 1.33), PCI without stenting (OR = 1.33), 
and diabetes (OR = 1.18). Older age (OR = 0.98) and prior use of other BASI medica-
tions (OR = 0.84) increased the adherence of clopidogrel. CONCLUSIONS: Prior use 
of clopidogrel and other heart medications, stenting, diabetes and other comorbidities 
affected the use and adherence of clopidogrel by ACS patients undergoing PCI. These 
ﬁndings may help programs that aim to improve thienopyridines adherence for 
increased effectiveness.
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OBJECTIVES: 1) To evaluate adherence to chronic disease (Diabetes, Hypertension, 
and Hyperlipidemia) medications of patients enrolled in an employer sponsored Medi-
cation Therapy Management (MTM) program. 2) To determine the effect of adherence 
on the clinical outcomes of patients with diabetes and hypertension in the MTM 
program. METHODS: This was a retrospective, longitudinal study. Adherence data 
was obtained from an independent pharmacy participating in an employer sponsored 
MTM program in the form of pharmacy reﬁll records for 272 patients. Clinical data 
was obtained through patient chart reviews. Medication adherence was calculated 
using Medication Possession Ratio (MPR) and weighted average adherence was cal-
culated for each class of medications. Pearson correlation was used to determine the 
relationship between medication adherence and desired clinical outcomes-HbA1c for 
diabetic patients and mean arterial pressure for hypertension patients. Multiple linear 
regression was used to determine if medication adherence was a predictor of clinical 
outcomes. Data analysis was performed using SPSS version16.0 and Microsoft Excel. 
RESULTS: Pearson correlation results indicated that MPR to diabetic medications 
was signiﬁcantly correlated with age (r = 0.387, p = 0.000) and gender (r = −0.167, 
p = 0.021). Further, age was signiﬁcantly correlated with number of diseases (r = 
0.278, p = 0.000) among diabetic patients. However, there were no signiﬁcant predic-
tors of change in A1c among diabetic patients. Among hypertension patients, change 
in mean arterial pressure was signiﬁcantly correlated with gender (r = 0.123 p = 0.037) 
and MPR (r = −0.146, p = 0.013). MPR was also found to be signiﬁcantly correlated 
with gender (r = −0.148, p = 0.012, co-pay (r = 0.142, p = 0.016), and number of 
diseases (r = 0.142, p = 0.016). Regression model for hypertension patients indicated 
that MPR (β = −0.136, p = 0.024) was a signiﬁcant predictor of change in mean arterial 
pressure. CONCLUSIONS: Patients enrolled in an employer sponsored MTM 
program showed high weighted average adherence to most of the classes of diabetes, 
hypertension, and hyperlipidemia medications. This study also identiﬁed predictors of 
clinical outcomes associated with diabetes and hypertension.
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OBJECTIVES: We examined the patterns of persistence among warfarin and other 
common chronic medications in patients with atrial ﬁbrillation (AF) and identiﬁed 
predictors of warfarin non-persistence. METHODS: We used a national, managed 
care claims dataset (January 1, 2005-December 31, 2007) to evaluate patterns of 
persistence in patients with AF. We examined those that ﬁlled a prescription for 
warfarin within 3 months following AF hospitalization discharge and had at least 
12-month continuous data prior to and following the ﬁrst ﬁll. For comparison, we 
also evaluated patterns of persistence for other selected, chronically-prescribed medi-
cations, including branded, generic, once-, twice-, and thrice-daily medications. Non-
persistence was deﬁned as failure to reﬁll the medication within 60 days from the 
run-out date of the prior prescription. Survival models were used to identify predictors 
of warfarin non-persistency. RESULTS: A total of 28,384 patients with AF were 
identiﬁed; 16,036 (56.5%) ﬁlled a warfarin prescription shortly following hospitaliza-
tion for AF. A total of 53.5% of warfarin users were persistent on warfarin for at 
least 1 year. Among non-persistent patients, average time to non-persistence was 122 
(SD 83) days from the ﬁrst warfarin prescription. Persistence with pioglitazone, sita-
gliptin, amlodipine, and once- and twice-daily carvedilol were similar to warfarin. 
While persistence with twice-daily carvedilol was similar to once-daily carvedilol 
phosphase (60.1% vs. 61.3%, p = 0.680), persistence of thrice-daily captopril was 
signiﬁcantly worse than that of once-daily amlodipine (27.7% vs. 51.9%, p < 0.001). 
Factors signiﬁcantly associated with time to non-persistence with warfarin included 
age, gender, residence in the south and west region, ischemic stroke, urinary tract 
infection, and warfarin out-of-pocket expense. CONCLUSIONS: Persistence with 
warfarin among patients with AF is consistent with other chronic medications. Per-
sistence with thrice-daily, but not twice-daily therapy was worse than once-daily 
medication. Factors associated with non-persistence can be used to identify patients 
and target adherence programs.
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OBJECTIVES: Most economic models in heart failure have been structured using New 
York Heart Association (NYHA) class to deﬁne mutually exclusive health states. With 
this structure, no utility (i.e. effectiveness) gains are measured in patients who experi-
ence important changes in health status but remain in the same NYHA class. We 
sought to evaluate whether the Kansas City Cardiomyopathy Questionnaire (KCCQ) 
summary score can further discriminate between patients with lower and higher health 
utilities within a given NYHA class. METHODS: Repeated measures of NYHA class, 
KCCQ, and EQ-5D utility scores were available from patients enrolled in HF-
ACTION, a randomized trial evaluating the effectiveness and safety of exercise train-
ing in addition to usual care compared to usual care alone in patients with chronic 
heart failure. We used generalized estimating equations to regress utility scores on 
NYHA class and demographic characteristics and to evaluate the impact of adding 
the KCCQ summary score in the regression models.RESULTS: A total of 12,649 sets 
of assessments were available from 2331 patients. The mean age of the study cohort 
was 59 years at baseline, 72% were male, 61% were white, and 32% were black. 
When controlling for age, gender and race, estimated utilities were 0.84 (95% CI: 
0.81–0.87) for NYHA class I, 0.80 (95% CI: 0.78–0.83) for class II, 0.75 (95% CI: 
0.72–0.78) for class III, and 0.65 (95% CI: 0.61–0.69) for class IV. A one-unit increase 
in the KCCQ summary score was associated with a 0.0044 (95% CI: 0.0042, 0.0045) 
increase in the utility weight, and its impact did not signiﬁcantly vary across NYHA 
classes. CONCLUSIONS: Use of KCCQ summary score in addition to, or instead of, 
NYHA class may provide more discriminatory power in terms of estimating incre-
mental gains in quality-adjusted life-years afforded by interventions for heart failure.
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OBJECTIVES: To demonstrate a simple, powerful, and ﬂexible approach to modeling 
the relationships between patient-reported outcomes and clinical measures over time. 
METHODS: Data were from 2,331 patients enrolled in the HF-ACTION (Heart 
Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing) trial. 
The patient-reported endpoint was the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) overall score and the clinical endpoint was peak VO2. We compared three 
different ways of measuring the association between changes in the KCCQ and peak 
VO2. The ﬁrst method (SIMPLE) computes change-from-baseline scores for each 
outcome. The second method (BLUP-1) used a linear mixed-effects model for each 
outcome to derive the best linear unbiased predictions (BLUP) of changes from 
baseline. The third method (BLUP-2) added 28 baseline covariates and their interac-
tions with time to the mixed model and then obtained BLUPs. For all three methods 
